➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
McKesson
Mallinckrodt
Johnson and Johnson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GSK2636771

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug GSK2636771?

GSK2636771 is an investigational drug.

There have been 7 clinical trials for GSK2636771. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2015.

The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), GlaxoSmithKline, and M.D. Anderson Cancer Center.

There are twelve US patents protecting this investigational drug and seventy-six international patents.

Recent Clinical Trials for GSK2636771
TitleSponsorPhase
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossGlaxoSmithKlinePhase 1/Phase 2
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossMerck Sharp & Dohme Corp.Phase 1/Phase 2
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN LossNational Cancer Institute (NCI)Phase 1/Phase 2

See all GSK2636771 clinical trials

Clinical Trial Summary for GSK2636771

Top disease conditions for GSK2636771
Top clinical trial sponsors for GSK2636771

See all GSK2636771 clinical trials

US Patents for GSK2636771

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GSK2636771   Start Trial Benzimidazole derivatives as PI3 kinase inhibitors GlaxoSmithKline LLC (Wilmington, DE)   Start Trial
GSK2636771   Start Trial Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof RACE ONCOLOGY LTD. (Melbourne, AU)   Start Trial
GSK2636771   Start Trial Benzimidazole derivatives as P13 kinase inhibitors GlaxoSmithKline LLC (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
McKesson
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.